相似文献
1
SARS-CoV-2 and Multiple Sclerosis: Not All Immune Depleting DMTs are Equal or Bad.
Ann Neurol. 2020 Jun;87(6):794-797. doi: 10.1002/ana.25770.
2
COVID-19, Mitochondria, and Interferon.
J Interferon Cytokine Res. 2020 Sep;40(9):466-467. doi: 10.1089/jir.2020.0112. Epub 2020 Jul 28.
3
Implications of COVID-19 Outbreak on Immune Therapies in Multiple Sclerosis Patients-Lessons Learned From SARS and MERS.
Front Immunol. 2020 May 12;11:1059. doi: 10.3389/fimmu.2020.01059. eCollection 2020.
4
Cyclosporine therapy during the COVID-19 pandemic.
J Am Acad Dermatol. 2020 Aug;83(2):e151-e152. doi: 10.1016/j.jaad.2020.04.153. Epub 2020 May 4.
5
Immune Responses to SARS-CoV, MERS-CoV and SARS-CoV-2.
Adv Exp Med Biol. 2020;1288:5-12. doi: 10.1007/5584_2020_549.
6
The role of IgG Fc receptors in antibody-dependent enhancement.
Nat Rev Immunol. 2020 Oct;20(10):633-643. doi: 10.1038/s41577-020-00410-0. Epub 2020 Aug 11.
7
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
Nature. 2020 Jul;583(7815):290-295. doi: 10.1038/s41586-020-2349-y. Epub 2020 May 18.
8
Multiple sclerosis and COVID-19: A great opportunity for databases promoting research and collaboration.
J Neuroimmunol. 2020 Aug 15;345:577283. doi: 10.1016/j.jneuroim.2020.577283. Epub 2020 May 31.
9
Evaluation of safety, efficacy, tolerability, and treatment-related outcomes of type I interferons for human coronaviruses (HCoVs) infection in clinical practice: An updated critical systematic review and meta-analysis.
Int Immunopharmacol. 2020 Sep;86:106740. doi: 10.1016/j.intimp.2020.106740. Epub 2020 Jun 25.
10
Silencing of immune activation with methotrexate in patients with COVID-19.
J Neurol Sci. 2020 Aug 15;415:116942. doi: 10.1016/j.jns.2020.116942. Epub 2020 May 25.
引用本文的文献
1
Trauma Burden Affected People with Multiple Sclerosis During SARS-CoV-2 Pandemic.
J Clin Med. 2025 Apr 13;14(8):2665. doi: 10.3390/jcm14082665.
2
Evaluating Risk: Benefit Ratio of Fat-Soluble Vitamin Supplementation to SARS-CoV-2-Infected Autoimmune and Cancer Patients: Do Vitamin-Drug Interactions Exist?
Life (Basel). 2022 Oct 20;12(10):1654. doi: 10.3390/life12101654.
3
COVID-19 severity among patients with multiple sclerosis treated with cladribine: A systematic review and meta-analysis.
Mult Scler Relat Disord. 2022 Dec;68:104156. doi: 10.1016/j.msard.2022.104156. Epub 2022 Sep 5.
4
Clinical Features of COVID-19 on Patients With Neuromyelitis Optica Spectrum Disorders.
Neurol Neuroimmunol Neuroinflamm. 2021 Aug 26;8(6). doi: 10.1212/NXI.0000000000001060. Print 2021 Nov.
5
COVID-19 severity and outcome in multiple sclerosis: Results of a national, registry-based, matched cohort study.
Mult Scler Relat Disord. 2021 Oct;55:103217. doi: 10.1016/j.msard.2021.103217. Epub 2021 Aug 16.
6
Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations.
Vaccines (Basel). 2021 Jul 11;9(7):773. doi: 10.3390/vaccines9070773.
7
COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: Insights from a nation-wide Austrian registry.
PLoS One. 2021 Jul 27;16(7):e0255316. doi: 10.1371/journal.pone.0255316. eCollection 2021.
8
SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry.
Neurol Neuroimmunol Neuroinflamm. 2021 Jun 24;8(5). doi: 10.1212/NXI.0000000000001024. Print 2021 Jul.
9
Risk and outcomes of COVID-19 in patients with multiple sclerosis.
Eur J Neurol. 2021 Nov;28(11):3712-3721. doi: 10.1111/ene.14990. Epub 2021 Jul 18.
10
The Epidemiology of COVID-19 and MS-Related Characteristics in a National Sample of People With MS in China.
Front Neurol. 2021 May 28;12:682729. doi: 10.3389/fneur.2021.682729. eCollection 2021.
本文引用的文献
1
Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover.
Pediatr Allergy Immunol. 2020 Jul;31(5):565-569. doi: 10.1111/pai.13263. Epub 2020 May 19.
2
COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?
Mult Scler Relat Disord. 2020 Jul;42:102120. doi: 10.1016/j.msard.2020.102120. Epub 2020 Apr 15.
3
Clinical characteristics of 3062 COVID-19 patients: A meta-analysis.
J Med Virol. 2020 Oct;92(10):1902-1914. doi: 10.1002/jmv.25884. Epub 2020 Jun 24.
4
Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients.
Emerg Microbes Infect. 2020 Dec;9(1):761-770. doi: 10.1080/22221751.2020.1747363.
5
Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic.
Liver Transpl. 2020 Jun;26(6):832-834. doi: 10.1002/lt.25756. Epub 2020 Apr 24.
6
COVID-19: consider cytokine storm syndromes and immunosuppression.
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
7
Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment.
Mult Scler Relat Disord. 2017 Nov;18:181-183. doi: 10.1016/j.msard.2017.09.028. Epub 2017 Sep 25.
8
Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab.
JAMA Neurol. 2017 Aug 1;74(8):961-969. doi: 10.1001/jamaneurol.2017.0676.
9
Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation.
J Neuroinflammation. 2017 Feb 23;14(1):41. doi: 10.1186/s12974-017-0817-6.
10
Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis.
EBioMedicine. 2017 Feb;16:41-50. doi: 10.1016/j.ebiom.2017.01.042. Epub 2017 Jan 31.
Zotero 插件